Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis

PLoS ONE(2022)10.1371/journal.pone.0274519Source: DataRank Database

Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis is a research paper published in PLoS ONE (2022). On theSindex it has a DataRank of 0. It has been cited 67 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access67 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 7.75)OA: goldTopics (38)Linked Datasets (4)DataCite Reuse (4)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Yi Dong ORCID,Jonas M. Ndeke ORCID,Juhua Luo ORCID,Michael Hendryx ORCID

Live enrichment

PubMed:36094949 PMC:PMC9467321 OpenAlex:https://openalex.org/W4295514438

National Institutes of Health

Grant: R03CA256238

National Institutes of Health

Grant: 5R03CA256238-02

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and lung cancer prognosis

FWCI

7.75

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0274519&type=printable

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0274519&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0274519

journalhttps://doi.org/10.1371/journal.pone.0274519

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36094949

Fields of Study

Diabetes Treatment and ManagementMetabolism, Diabetes, and CancerPancreatic function and diabetes0301 basic medicine03 medical and health sciences

MeSH Terms

Sodium-Glucose Transporter 2 InhibitorsAgedDiabetes Mellitus, Type 2GlucoseMedicareCarcinoma, HepatocellularHumansLiver NeoplasmsPrognosisSodiumUnited States

Keywords

Hepatocellular carcinomaCotransporterSodiumMedicineInternal medicineChemistryCarcinoma, HepatocellularScienceQLiver NeoplasmsRMedicarePrognosisUnited StatesSodium-glucose transporter 2 IinhibitorsGlucoseDiabetes Mellitus, Type 2Type 2 diabetes mellitusHumansSodium-Glucose Transporter 2 InhibitorsResearch ArticleAged

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis

10.6084/m9.figshare.25876111.v1figshare

Additional file 1 of Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis

10.6084/m9.figshare.25876111figshare

Additional file 2 of Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis

10.6084/m9.figshare.25876346.v1figshare

Additional file 2 of Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis

10.6084/m9.figshare.25876346figshare